Use of abciximab during infrainguinal peripheral vascular interventions: Initial experience

Radiology

Volumn 227, Issue 3, 2003, Pages 657-661

  Stavropoulos, S William ^a   Solomon, Jeffrey A ^a   Soulen, Michael C ^a   Clark, Timothy W I ^a   Shlansky Goldberg, Richard D ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Arteries; Femoral Arteries; Popliteal Arteries; Stenosis or obstruction; Transluminal angioplasty

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; HEPARIN;

ADJUVANT THERAPY; ADULT; AGED; ANGIOPLASTY; ARTERY OCCLUSION; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CORONARY STENT; FEMALE; GINGIVA BLEEDING; HEMATOMA; HUMAN; MALE; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PERIPHERAL VASCULAR DISEASE; POPLITEAL ARTERY; PRIORITY JOURNAL; SUPERFICIAL FEMORAL ARTERY; THROMBOCYTE COUNT; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGIOPLASTY, BALLOON; ANTIBODIES, MONOCLONAL; ARTERIAL OCCLUSIVE DISEASES; CONSTRICTION, PATHOLOGIC; FEMALE; FEMORAL ARTERY; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; POPLITEAL ARTERY;

EID: 0037950471     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2273020130     Document Type: Article

References (22)

1. Truong KM, Amankwa K, Kucukarslan S. Platelet glycoprotein IIb/IIIa-receptor inhibitors in patients with acute coronary syndromes or undergoing percutaneous coronary interventions: a review. Clin Ther 2001; 23:1145-1165.
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994; 330:956-961.
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPILOG Investigators. N Engl J Med 1997; 336:1689-1696.
4. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. The EPISTENT Investigators. Evaluation of Platelet IIb/IIIa Inhibitor for Stenting. Lancet 1998; 352:87-92.
5. Lange RA, Hillis LD. Reperfusion therapy in acute myocardial infarction (letter). N Engl J Med 2002; 346:954-955.
6. Topol EJ, Yadav JS. Recognition of the importance of embolization in atherosclerotic vascular disease. Circulation 2000; 101:570-580.
7. Kapadia SR, Bajzer CT, Ziada KM, et al. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy. Stroke 2001; 32:2328-2332.
8. Qureshi AI, Suri MF, Khan J, Fessler RD, Guterman LR, Hopkins LN. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience. Neurosurgery 2000; 46:1316-1325.
9. Schneiderman J, Morag B, Gerniak A, et al. Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results. J Endovasc Ther 2000; 7:263-272.
10. Clark TWI, Groffsky JL, Soulen MC. Predictors of long-term patency after femoropopliteal angioplasty: results from the STAR registry. J Vasc Interv Radiol 2001; 12:923-933.
11. Sacks D, Marinelli DL, Martin LG, et al. Reporting standards for clinical evaluation of new peripheral arterial revascularization devices. J Vasc Interv Radiol 1997; 8:137-149.
12. Rutherford R, Becker G. Standards for evaluating and reporting the results of surgical and percutaneous therapy for peripheral arterial disease. J Vasc Interv Radiol 1991; 2:169-174.
13. Topol EJ, Ferguson JJ, Weisman HF, et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 1997; 278:479-484.
14. Topol E, Califf R, Wiesman HF, et al. Randomised trial of coronary interventions with antibody against IIb/IIIa integrin for reduction of clinical restenosis. Lancet 1994; 343:881-886.
15. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). The ERASER Investigators. Circulation 1999; 100:799-806.
16. Benenati J, Shlansky-Goldberg R, Meglin A, et al. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. Society for Cardiovascular and Interventional Radiology. J Vasc Interv Radiol 2001; 12:795-805.
17. Schweizer J, Kirch W, Koch R, et al. Shortand long-term results of abciximab versus aspirin in conjunction with thrombolysis for patients with peripheral occlusive arterial disease and arterial thrombosis. Angiology 2000; 51:913-923.
18. Drescher P, Crain MR, Rilling WS. Initial experience with the combination of reteplase and abciximab for thrombolytic therapy in peripheral arterial occlusive disease: a pilot study. J Vasc Interv Radiol 2002; 13:37-43.
19. Shlansky-Goldberg R. Platelet aggregation inhibitors for use in peripheral vascular interventions: what can we learn from the experience in the coronary arteries? J Vasc Interv Radiol 2002; 13:229-246.
20. Tetteroo E, van der Graaf Y, Bosh JL, et al. Randomised comparison of primary stent placement versus primary angioplasty followed by selective stent placement in patients with iliac-artery occlusive disease. Dutch Iliac Stent Trial Study Group. Lancet 1998; 351:1153-1159.
21. Dorros G, Jaff MR, Dorros AM, Mathiak LM, He T. Tibioperoneal (outflow lesion) angioplasty can be used as primary treatment in 235 patients with critical limb ischemia: five-year follow-up. Circulation 2001; 104:2057-2062.
22. Soder HK, Manninen HI, Jaakkola P, et al. Prospective trial of infrapopliteal artery balloon angioplasty for critical limb ischemia: angiographic and clinical results. J Vasc Interv Radiol 2000; 11:1021-1031.